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Abstract
Cellular therapies based on mesenchymal stromal/stem cells (MSC) are promising strategies in regenerative medicine and
oncology. Despite encouraging results, there is still some level of concerns on inoculating MSC in cancer patients. To face
this issue, one possibility resides in engineering MSC by incorporating a suicide gene in order to control their fate once
infused. Strategies based on Herpes Simplex Virus Thymidine Kinase (HSV-TK) and the Cytosine Deaminase genes have
been developed and more recently a novel suicide gene, namely, iCasp9, has been proposed. This approach is based on a
variant of human Caspase9 that binds with high affinity to a synthetic, bioinert small molecule (AP20187) leading to cell
death. Based on this technology so far marginally applied to MSC, we tested the suitability of iCasp9 suicide strategy in
MSC to further increase their safety. MSC have been transfected by a lentiviral vector carrying iCasp9 gene and then tested
for viability after AP20187 treatment in comparison with mock-transfected cells. Moreover, accounting our anti-tumor
approaches based on MSC expressing potent anti-cancer ligand TNF-Related Apoptosis-Inducing Ligand (TRAIL), we
generated adipose MSC co-expressing iCasp9 and TRAIL successfully targeting an aggressive sarcoma type. These data
show that anti-cancer and suicide mechanisms can coexist without affecting cells performance and hampering the
tumoricidal activity mediated by TRAIL. In conclusion, this study originally indicates the suitability of combining a MSC-
based anti-cancer gene approach with iCasp9 demonstrating efficiency and specificity.
Introduction
Mesenchymal stromal/stem cells (MSC) are a hetero-
geneous population of fibroblast-like cells originally
isolated from bone marrow and other tissues including
adipose tissue, peripheral blood, umbilical cord blood, and
Wharton’s jelly, among others [1, 2]. MSC retain ther-
apeutic potential in several pathological conditions through
different mechanisms such as differentiation into mature
cells, secretion of cytokines, and release of microvesicles
[3, 4]. Moreover, growing evidences revealed that MSC
retain unique immunological features that are relevant for
the treatments of immune-related disorders [5] and for their
possible use as cellular vehicles to deliver bioactive mole-
cules inside tumor parenchyma and stroma [6]. In particular,
this latter possibility gained a relevant interest in the last
decade and we and others have been developing anti-tumor
approaches based on MSC expressing the potent anti-cancer
ligand TNF-Related Apoptosis-Inducing Ligand (TRAIL),
variants demonstrating efficacy against several tumors [7–9,
Spano et al., Submitted].
Despite encouraging results, there is some level
of concern regarding the safety of inoculating both wild-
type and gene-modified MSC in particular concerning
their possible damage to normal organs, malignant
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transformation, and promotion of cancer growth [10]. One
possibility to face these possibilities is to incorporate a
suicide gene in MSC; the most commonly used are the
Herpes Simplex Virus Thymidine Kinase and the Cyto-
sine Deaminase [11]. These transgenes confer the ability
to convert a non-toxic prodrug into an active cytotoxic
compound that kills the cell itself and the neighbors. This
“bystander effect” has been exploited to specifically
deliver cytotoxic compounds into tumor burdens with
therapeutic benefit limiting possible off target toxicity
[12]. However, these systems demonstrated a number of
disadvantages starting from their possible immunogeni-
city with consequent elimination by immune system [13]
and the high cell-cycle dependency of the activated drugs
that limits killing capacity to dividing cells [14]. Addi-
tional drawbacks may also come from the limitation in
concurrent administration of drugs (i.e., Ganciclovir) that,
delivered for a possible CMV-viral infection, can lead to
unintended elimination of gene-modified cells [15]; fur-
ther evidences indicate also the possible onset of drug
resistance on target cells [16].
In recent years, alternative strategies have been devel-
oped to overcome these limitations. In particular, investi-
gators described a novel suicide gene, namely, iCasp9,
based on the sequence of human Caspase9 encoding for a
modified protein having a high affinity to a synthetic,
bioinert small molecule (B/B Homidimerizer, AP20187)
resulting in iCasp9 dimerization and activation eventually
leading to cell death [15]. This approach offers several
advantages over the other suicide strategies, such as the
human origin of the protein, as favorable condition to avoid
immunogenicity. Moreover, the suicide trigger is indepen-
dent from the cell cycle phase and does not interfere with
any drug schedule [15]. Several studies showed the high
efficacy and specificity of iCasp9 [10, 17, 18] and a safety
study on healthy volunteers demonstrated the feasibility of
the treatment with the dimerizer molecule in humans [19].
Based on this background, we challenge this approach on
anti-cancer MSC delivering TRAIL to generate a proof of
concept that would ultimately increase the safety of our cell
therapy approach.
Materials and methods
Cell culture
The human embryonic kidney cell line 293T and the human
Ewing sarcoma cell line A673, both from our laboratory,
were maintained in culture at 37 °C in Dulbecco’s Modified
Eagle’s Medium (Gibco, Thermo Fisher Scientific Inc.,
Waltham, MA, USA) supplemented with 10% fetal bovine
serum (PAA Laboratories Inc., Etobicoke, Canada), 1%
penicillin/streptomycin (10,000 U/mL Penicillin, 10 mg/mL
Streptomycin in 0.9% NaCl solution, PAA Laboratories
Inc.). Adipose-derived MSC (AD-MSC) were obtained as
previously described from lipoaspirate specimens of indi-
viduals undergoing liposuction for esthetic purposes after
approval by local Ethical Committee [7]. Cells from two
different donors were used as biological replicates. After
isolation, cells were grown in α-MEM (Gibco) containing
2.5% human platelet lysate (Modena Policlinic Blood
Bank, Modena, Italy), 1% L-Glutamine (200 mM in 0.85%
NaCl solution, BioWhittaker, Lonza, Verviers, Belgium),
0.5% Ciprofloxacin (Fresenius Kabi Italia S.r.l., Verona,
Italy), 1 IU/ml Heparin (Sigma-Aldrich, St. Louis, MO,
USA). When confluent, the adherent AD-MSC cells were
detached with trypsin/EDTA (Trypsin 0.05% EDTA 0.02%
in PBS, EuroClone, Milan, Italy), counted and seeded at
6000 cells/cm2. Cells were incubated and maintained
within a controlled atmosphere (5% CO2 and temperature of
37 °C).
Vector generation and MSC transduction
The pMSCV-F-del Casp9.IRES.GFP plasmid was obtained
from Addgene repository (Addgene plasmid #15567,
http://www.addgene.org/). iCasp9 gene was subcloned into
a third-generation lentiviral backbone (pCCL.PGK.WPRE)
and the resulting construct was transiently transfected into
293T cells together with a mixture of helper plasmids
according to jetPEI® protocol (Polyplus Transfection, Ill-
kirch, France). After 48 h, conditioned medium containing
lentiviral particles was collected and used to transduce AD-
MSC, thus obtaining AD-MSC iCasp9. AD-MSC expres-
sing TRAIL (AD-MSC TRAIL) from our laboratory [7]
have been further engineered in the same way to express
iCasp9 gene (AD-MSC TRAIL-iCasp9). AD-MSC trans-
duced with the empty lentiviral backbone were used as
control (AD-MSC EMPTY).
Dose-response apoptosis induction assay
Modified AD-MSC were tested for apoptosis induction after
the addition of B/B Homodimerizer (AP20187, Clontech
Laboratories, Inc., Mountain View, CA, USA) by MTS
metabolic assay (CellTiter® 96 AQueous One Solution Cell
Proliferation Assay, Promega Corporation, Madison, WI,
USA). Briefly, for each tested sample and dimerizer con-
centration, 5000 cells were seeded in a well of a 96-wells
plate. The following day, medium was replaced with fresh
one containing different concentrations of B/B Homo-
dimerizer (0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM), and
after 24 h the plate was analyzed with a Multiskan FC
Microplate Photometer (Thermo Fisher Scientific Inc.),
according to manufacturer’s instructions.
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AD-MSC TRAIL-iCasp9 cytotoxicity assay
AD-MSC TRAIL-iCasp9 have been then tested for cyto-
toxic activity against the A673 cell line through a 51Cr
release assay in coculture and compared with AD-MSC
TRAIL and AD-MSC EMPTY. Briefly, tumor cells were
labeled with 51Cr and then cultured alone or together with
AD-MSC, AD-MSC TRAIL, or AD-MSC TRAIL-iCasp9
for 8 and 24 h at several ratio of target:effector cells (1:1,
1:2, 1:5). 51Cr released has been detected by 2450
microplate counter MicroBeta2TM (PerkinElmer, Wal-
tham, MA, USA). The experiment layout comprises a
maximum 51Cr release condition obtained by lysing 51Cr-
marked cells with Triton X-100 (Sigma-Aldrich) and a
background assessment obtained by measuring the beta
emission of untreated 51Cr-marked cells. The background
level is subtracted from all the measures, while the max-
imum release becomes the reference for 100% mortality in
respect of which all the other death rates are calculated. In
addition, to test whether unaffected cells developed
resistance against the B/B Homodimerizer treatment, we
proceeded with a three-hit suicide induction assay. AD-
MSC EMPTY and iCasp9 were seeded in three 96-well
plates corresponding to the conditions tested and incu-
bated with 10 nM B/B Homodimerizer (1st hit). After 24 h
mortality rate was assessed in one of the plates by MTS
metabolic assay, while the others were incubated again
with 10 nM dimerizer (2nd hit). After additional 24 h, the
second plate was evaluated while the remaining one was
induced for the last time (3rd hit) for 24 h.
AD-MSC TRAIL-iCasp9 combined assay
Cytotoxicity and suicide assays were combined together in
a comprehensive assay to test whether AD-MSC TRAIL-
iCasp9 could be induced to suicide after cytotoxic effect.
A673 cells were seeded in 12-well multiwell plate at a
density of 6000 cells/cm2. The following day, AD-MSC
EMPTY, AD-MSC TRAIL, and AD-MSC TRAIL-iCasp9
were stained with CFSE (CellTrace™ CFSE Cell Pro-
liferation Kit, Thermo Fisher Scientific Inc.), according to
manufacturer’s protocol and seeded in coculture with A673
cells at 12,000 cells/cm2 (1:2 A673:MSC ratio). After 24 h
of coculture, 10 nM B/B Homodimerizer was added and
induction lasted 18 h. At that point cells were stained with
propidium iodide 50 µg/mL (stock solution 1 mg/ml in PBS,
Sigma-Aldrich) for 30 min, detached and then the percen-
tage of dead cells was detected by flow cytometry (FACS
Aria III, BD Biosciences, San Diego, CA, USA). In parti-
cular, apoptotic MSC were identified as both CFSE and PI
positive, while A673 apoptotic cells were CFSE negative
and PI positive.
Statistical analyses
All experiments have been performed three times with a
technical triplicate. Data have been analyzed using Micro-
soft Excel 2010 (Microsoft Corporation, Redmond, WA,
USA) and are expressed as mean values ± SD unless
otherwise noted. Normal distribution of data have been
tested using Shapiro–Wilk normality test. Unpaired two-
tailed Student’s t-test was used considering p ≤ 0.05 as
statistically significant. ANOVA test was performed using
Prism software (GraphPad Software Inc., La Jolla, CA,
USA) considering p ≤ 0.05 as statistically significant.
Results
AD-MSC expressing iCasp9 efficiently undergo
apoptosis after induction
Dose-response assay showed that the addition of B/B
Homodimerizer efficiently triggers apoptosis in both AD-
MSC iCasp9 and AD-MSC TRAIL-iCasp9 (Fig. 1). In
particular, after 24 h of treatment, we observed an initial
drop in cell viability with concentration of dimerizer as low
as 0.01 nM. The increase in concentration corresponded to a
decrease in cell viability, reaching 18.3 ± 0.5% for AD-
MSC TRAIL-iCasp9 at the 100 nM concentration. Notice-
ably, apoptosis for both AD-MSC iCasp9 and AD-MSC
TRAIL-iCasp9 cells reached a plateau at 1 nM with no
difference due to the presence of the TRAIL gene. In the
same experimental setting, EMPTY-modified cells were not
affected by the presence of dimerizer molecule in all the
tested concentrations and time points.
Fig. 1 AD-MSC expressing iCasp9 efficiently undergo apoptosis after
treatment with B/B Homodimerizer. Dose-response assay in MTS
showed the effect on vitality of 24 h incubation with several B/B
Homodimerizer concentrations. We observed a progressive drop in
cell viability of both AD-MSC iCasp9 and TRAIL-iCasp9 reaching
20% at 100 nM. While the slope is more pronounced for AD-MSC
TRAIL-iCasp9, both cell populations reached a similar plateau at 10
nM. The treatment had no effect on AD-MSC Empty. °p < 0.0001,
*p < 0.0001, **p < 0.01 by ANOVA and multiple comparison tests
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AD-MSC TRAIL-iCasp9 retain cytotoxic potential
against Ewing Sarcoma cell line
The 51Cr release coculture assay demonstrated that iCasp9
expression does not affect AD-MSC TRAIL cytotoxic
activity. As shown in Fig. 2, AD-MSC expressing both
iCasp9 and TRAIL are able to kill A673 Ewing Sarcoma
cells with an efficacy very similar to that of AD-MSC
expressing TRAIL only. The effect has been clearly
appreciable even starting from 8 h of culture and becoming
more prominent after 24 h. Moreover, we observed an
upward trend in MSC cytotoxic capacity as the ratio
between tumor cells and MSC decreases, reaching 72.9 ±
11.0% at the lowest T:E ratio of 1:5.
Surviving AD-MSC iCasp9 maintain sensitivity for
the dimerizing treatment
AD-MSC iCasp9 surviving after 24 h incubation with a first
round of B/B Homodimerizer were again treated by the
same protocol to assess whether AD-MSC iCasp9 gained
resistance. Interestingly, repeated hits showed an aug-
mented mortality rate at each treatment which increases
from 71.1 ± 0.4 to 83.8 ± 0.3%, excluding the development
of a resistance (Fig. 3).
AD-MSC TRAIL- iCasp9 can be induced to apoptosis
after death induction in sarcoma cells
To in vitro validate our suicide strategy, gene-modified AD-
MSC were cultured with A673 and then induced to suicide
after their cytotoxicity effect had taken place. As visible in
Fig. 4, both A673 alone and AD-MSC EMPTY, as controls,
showed expected mortality levels with no impact of the
dimerizer in both cell types. A673 cultured with AD-MSC
TRAIL showed high levels of apoptosis with no effect of
Fig. 2 iCasp9 expression does not impair TRAIL-mediated anti-sar-
coma cytotoxicity. The 51Cr release coculture assay showed a similar
cytotoxic capacity of AD-MSC TRAIL and TRAIL-iCasp9. In parti-
cular at 1:1 ratio, death rate in coculture with AD-MSC TRAIL
increased from 15.5 ± 3.5% after 8 h to 32.4 ± 12.3% after 24 h, at 1:2
ratio increased from 28.6 ± 4.1% after 8 h to 48.5 ± 10.7% after 24 h,
and at 1:5 ratio increased from 36.3 ± 6.5% after 8 h to 76.0 ± 12.4%
after 24 h. Similarly, in coculture with AD-MSC TRAIL-iCasp9, at 1:1
ratio death rate increased from 15.8 ± 6.1% after 8 h to 44.2 ± 5.9%
after 24 h, at 1:2 ratio increased from 27.7 ± 5.2% after 8 h to 54.3 ±
7.3% after 24 h, and at 1:5 ratio increased from 29.3 ± 5.6% after 8 h to
72.9 ± 11.0% after 24 h. UDL UnDetectable Lysis. *p < 0.01, **p <
0.05 by Student’s t-test. Data are expressed as mean ± SEM
Fig. 3 Treatment can progressively eliminate AD-MSC iCasp9. AD-
MSC EMPTY or iCasp9 have been treated with 10 nM B/B Homo-
dimerizer from 1 to 3 times. The first 24 h of incubation led to 71.1 ±
0.4% of cell apoptosis and a subsequent identical treatment on sur-
vived cells led to 79.7 ± 0.3% cell death. Futhermore another 24 h
treatment improved suicide rate up to 83.8 ± 0.3%. These data show
that treatment can be repeated to eradicate still alive cells. *p < 0.01 by
Student’s t-test. Data are expressed as mean ± SEM
Fig. 4 AD-MSC TRAIL-iCasp9 can be prompted to apoptosis after
cytotoxic action. Modified MSC were first engaged against tumor cells
and then induced to suicide after the completion of cytotoxic activity.
This assay confirmed the cytotoxic action of TRAIL-expressing MSC
with 59.4 ± 2.2% and 61.2 ± 3.6% A673 cell death in coculture with
AD-MSC TRAIL and TRAIL-iCasp9, respectively (A673 basal death
rate: 24.1 ± 6.9%) and, from the other side, it recapitulates the pro-
posed approach in which iCasp9-expressing MSC can be committed to
apoptosis (45.9 ± 3.1%). *p < 0.01 by Student’s t-test
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the dimerizer on AD-MSC TRAIL. Very interestingly, the
AD-MSC TRAIL-iCasp9 confirmed their sarcoma-killing
capacity followed by their induction to apoptosis by the
dimerizing agent. Collectively these findings indicated that
our strategy to induce cancer cell apoptosis by MSC and
then eliminate the effector cells is feasible.
Discussion
Theoretically, cell-based therapies require transplanted cells
to survive until the stabilization of their therapeutic func-
tion. However, the ability of controlling in the long-term
unwanted behaviors of successfully transplanted cells still
represent a critical point in safety management. Although
MSC have been administered to hundreds of patients
without notable side effects, some level of concerns persists
especially in regard to gene-modified cells [10]. Thus, to
improve the safety of our cell therapy approach we intro-
duced, within a gene-modified MSC platform, a novel
suicide mechanism based on an engineered form of Cas-
pase9 which is activated only in presence of a specific
dimerizer molecule. This safety mechanism hold promises
for an almost complete elimination of modified cells in case
of adverse reactions after infusion. This technology was first
described by Straathof and colleagues followed by other
groups which demonstrated its potential for the elimination
of modified T lymphocytes in preclinical [14, 15, 20] and
clinical [18] scenarios. However, to the best of our
knowledge, studies on its application on MSC is only lim-
ited to unmodified bone marrow-derived MSC [10]. Here,
we are originally presenting a suicide gene strategy in
combination with a TRAIL gene delivery approach for
cancer. By this strategy we were able to induce cancer cell
death up to 80% in 24 h. While this impact is relevant, we
are currently exploring optimized strategies to increase the
mortality possibly by the combination of synergizing agents
to MSC-delivered TRAIL, as we previously showed using
bortezomib against a poorly TRAIL-sensitive triple-nega-
tive breast cancer [7] and as more broadly reported by
Trivedi et al. [21].
Testing the approach on AD-MSC gene modified to
express iCasp9 construct we observed a remarkable rate of
cell elimination after the addition of the dimerizer molecule
with almost 80% of iCasp9 expressing MSC eliminated
after a single dose of dimerizer. On contrary, unmodified
cells are not affected by the treatment, thus confirming its
specificity. We further include the iCasp9 system in our
gene-modified MSC expressing TRAIL and verified that the
cytotoxic activity is not hampered by the presence of iCasp9
gene. In particular, we observed a similar cytotoxic activity
between MSC TRAIL and TRAIL-iCasp9, in line with our
previous observations in vitro [7], thus demonstrating the
feasibility of the combined approach. Moreover, the double
infection was not interfering with iCasp9-mediated clear-
ance of modified cells and in fact we still observed
approximately 85% of cell death in double-infected cells.
Nonetheless, an optimization of transfection technology
with an improved selection of gene-modified MSC will
rather be desirable to more solidly prompt this technology
into clinical studies, as already performed for T
lymphocytes-based therapies [18]. In the MSC and cancer
arena, Neiss et al. pre-clinically gene modified human MSC
by a vector containing the HSV-TK gene [22]. In that case
transduction efficacy was between 2–30% and required a
puromycin treatment. After the selection they were able to
safely treat six patients with advanced, recurrent, or meta-
static gastrointestinal or carcinoma within a phase I/II study
[23]. An increase up to 100% in the level of apoptosis in
target cells after activation of the suicide mechanism would
also be desirable, although a substantial therapeutic benefit
in patients affected by graft-versus-host disease has been
achieved even when 90% of T lymphocytes have been
killed [18].
Potential limitations of this strategy include the occur-
rence of spontaneous dimerization of iCasp9 causing
undesirable cell death. Although this cannot be excluded in
advance, our and other’s observation of low spontaneous
death rate argues against the relevance of this point [10].
Another potential limit is the development of resistance due
to the upregulation of anti-apoptotic effectors. Nonetheless
the involvement of Caspase9 occurs late in the apoptotic
pathway and it should therefore bypass the effects of these
regulators. We glanced at this issue by verifying that cells
surviving to the first administration of dimerizer do not
develop a resistance to the treatment and can be killed by a
subsequent administration, thus ensuring the reliability of
the approach. With the limitation of an in vitro study, these
data represent proof-of-concept that it is possible to mod-
ulate the survival of gene-modified MSC influencing their
tumor killing ability increasing the efficacy of the approach
with the release of anticancer agent within the tumor
microenvironment and at the same time to control the
possible side effects within more efficient and safe cancer
gene therapy strategies.
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